Sarah B. Goldberg on New Immunotherapy Options for Patients With Lung Cancer

APPs provide an in-depth look at amivantamab plus lazertinib for the treatment of patients with locally advanced or metastatic non–small cell lung cancer.

Nicole Gay, APRN-C, shares how nurse navigators can talk to their patients about lung cancer screening.

The agency granted approval to durvalumab for the treatment of a subset of patients with limited-stage small cell lung cancer.

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

Based on findings from a phase 2 expansion cohort, the FDA granted breakthrough therapy designation to sacituzumab tirumotecan for use in select patients with EGFR+ non–small cell lung cancer.

According to the American Lung Association, biomarker testing gaps and low screening rates continue to hinder lung cancer survival; however, rates have improved in the last 5 years regardless.